Literature DB >> 19042946

Determination of the irradiation field for clinical T1-T3N0M0 thoracic/abdominal esophageal cancer based on the postoperative pathological results.

Tatsuya Nakamura1, Syunzo Hatooka, Takeshi Kodaira, Hiroyuki Tachibana, Natsuo Tomita, Rie Nakahara, Haruo Inokuchi, Nobutaka Mizoguchi, Akinori Takada, Masayuki Shinoda, Nobukazu Fuwa.   

Abstract

OBJECTIVE: In patients with thoracic/abdominal esophageal cancer with no clinical evidence of lymph node metastasis, there is no consensus about whether the irradiation field should include regional lymph nodes. In this study, the extent of the irradiation field for clinical stage T1-3N0M0 esophageal cancer was determined based on the postoperative pathological results.
METHODS: From July 1989 to June 2008, 103 patients diagnosed with clinical stage T1-3N0M0 thoracic/abdominal esophageal cancer underwent standard esophagectomy and regional lymph node dissection at the Aichi Cancer Center Hospital. Of these 103 patients, the pathological results of the resected specimens could be confirmed in 95 (92%) patients. The pathological lymphatic spread was reviewed retrospectively, and the extent of the irradiation field was determined based on the postoperative pathological results.
RESULTS: Of 95 patients with clinical stage T1-3N0M0 esophageal cancer, 40 (42.1%) had pathological lymph node metastases, and the frequency of nodal metastases was studied by tumor location. The rates of lymph node metastases for the upper, middle, lower and abdominal esophagus were 37.5%, 32.5%, 46% and 70%, respectively.
CONCLUSIONS: Pathological lymph nodes metastases are often seen after operation in clinical stage T1-3N0M0 esophageal cancer. In the present study, the optimal lymph nodes to be included in the irradiation field were determined according to the primary site in the esophagus.

Entities:  

Mesh:

Year:  2008        PMID: 19042946     DOI: 10.1093/jjco/hyn131

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

1.  Precise delineation of clinical target volume for crossing-segments thoracic esophageal squamous cell carcinoma based on the pattern of lymph node metastases.

Authors:  Yuanli Dong; Hui Guan; Wei Huang; Zicheng Zhang; Dongbo Zhao; Yang Liu; Tao Zhou; Baosheng Li
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

2.  Radiation therapy in the postoperative management of esophageal cancer.

Authors:  Salma K Jabbour; Charles R Thomas
Journal:  J Gastrointest Oncol       Date:  2010-12

3.  Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era.

Authors:  Arya Amini; Lianchun Xiao; Pamela K Allen; Akihiro Suzuki; Yuki Hayashi; Zhongxing Liao; Wayne Hofstetter; Christopher Crane; Ritsuko Komaki; Manoop S Bhutani; Jeffrey H Lee; Jaffer A Ajani; James Welsh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-19       Impact factor: 7.038

4.  Radiation dose to the lymph drainage area in esophageal cancer with involved-field irradiation.

Authors:  Wenbin Shen; Hongmei Gao; Shuchai Zhu; Youmei Li; Juan Li; Zhikun Liu; Jinwei Su
Journal:  Oncol Lett       Date:  2015-11-23       Impact factor: 2.967

5.  Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer.

Authors:  Akinori Takada; Tatsuya Nakamura; Kanako Takayama; Chiyoko Makita; Motohisa Suzuki; Yusuke Azami; Takahiro Kato; Iwao Tsukiyama; Masato Hareyama; Yasuhiro Kikuchi; Takashi Daimon; Yutaka Toyomasu; Noriko Ii; Yoshihito Nomoto; Hajime Sakuma; Nobukazu Fuwa
Journal:  Cancer Med       Date:  2016-01-24       Impact factor: 4.452

Review 6.  What Is the Appropriate Clinical Target Volume for Esophageal Squamous Cell Carcinoma? Debate and Consensus Based on Pathological and Clinical Outcomes.

Authors:  Dali Han; Yinping Yuan; Xuqing Song; Yonghua Yu; Jinming Yu
Journal:  J Cancer       Date:  2016-01-01       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.